Piseth Suor
Physician Assistant · Stockton, CANPI 1699054809
Payments from drug & device makers
Across 1,239 payments — averaging $22.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- AstraZeneca$2K
- AbbVie$2K
- Lilly USA, LLC$2K
- GSK$2K
- Boehringer Ingelheim$2K
- plus $17K from 54 others
What the payments were for
- Food & beverage$28,06299%
- Education$1801%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,241 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Synjardy XrEmpagliflozin/Metformin Hcl | 865 | $605,335 |
| RybelsusSemaglutide | 348 | $373,996 |
| OzempicSemaglutide | 328 | $333,733 |
| JardianceEmpagliflozin | 233 | $189,659 |
| TradjentaLinagliptin | 182 | $123,625 |
| Xigduo XrDapaglifloz Propaned/Metformin | 207 | $120,541 |
| VascepaIcosapent Ethyl | 212 | $110,271 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $84,171 |
| LinzessLinaclotide | 105 | $79,831 |
| KerendiaFinerenone | 94 | $68,934 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 67 | $58,949 |
| FarxigaDapagliflozin Propanediol | 70 | $50,156 |
| GemtesaVibegron | 119 | $43,355 |
| Icosapent Ethyl | 145 | $40,645 |
| VemlidyTenofovir Alafenamide | 30 | $39,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Jardiance, Tradjenta, Combivent Respimat | $1,595 | $929,6501,302 claims |
| Novo NordiskRybelsus, Ozempic, Xultophy 100-3.6 | $2,910 | $725,004690 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,655 | $125,069210 claims |
| AbbVieLinzess | $1,791 | $79,831105 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,839 | $78,678134 claims |
| BayerKerendia | $1,154 | $68,93494 claims |
| MerckJanumet Xr, Januvia | $368 | $62,15071 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $319 | $58,94967 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $143 | $43,355119 claims |
| GileadVemlidy | $570 | $39,34030 claims |
| PfizerEliquis | $866 | $31,45855 claims |
| Johnson & JohnsonXarelto, Invokamet | $161 | $29,48544 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Stockton
- John QuigleyDowney$2.9M
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
- Eric CheungLos Angeles$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.